Corporate responsibility is ingrained in Celgene’s purpose—“to change the course of human health through bold pursuits in science and a promise to always put patients first.”
With that responsibility guiding all business activities, the company is focusing on its mission to discover, develop and deliver to patients innovative medicines that are contributing to human well-being in the areas of hematology, oncology and immunology and inflammation. Over the past five years, more than 30 percent of the company’s revenue has been reinvested in research and development, which is well above the industry average. This reinvestment helps support the company’s 22 clinical development programs, with 28,000 patients enrolled in more than 100 Celgene-sponsored clinical trials.
“What our investment shows is a real commitment to thinking beyond the short-term and ensuring sustainable medical innovation to benefit patients today and in the future,” said Zeba Khan, Vice President of Corporate Responsibility at Celgene.
Celgene also knows that commitment requires helping patients gain access to medications they need.
Consequently, Celgene works with advocates, doctors, healthcare providers, payers and policymakers to advocate for patient rights to affordable access to effective new therapies. That commitment to patients landed Celgene in first place in the 2014 STAR report in hematology advocacy support.
And since 2007, Celgene has helped more than 20,000 patients gain access to the therapies that they need through Celgene Patient Support®, a free service which helps patients understand their health insurance, offers financial assistance for copays to those who qualify and provides access to medications for the uninsured or underinsured.
The company’s commitment to medical innovation also extends to responsible and transparent sharing of clinical trial data with patients, healthcare practitioners and independent researchers to improve scientific and medical knowledge. Celgene is a member of the CEO Roundtable on Cancer, a nonprofit corporation comprised of chief executives from major American companies that are committed to fighting cancer.
The Life Sciences Consortium, within the CEO Roundtable, recently launched the Project Data Sphere initiative, aimed at creating a platform to share clinical trial data across the cancer research environment. By employing advanced data security and anonymization strategies, the project seeks to find innovative solutions for cancer patients by using historical clinical trial data to accelerate research and discovery. Celgene is proud to be a founding member of the Project Data Sphere initiative and to give back to the patients who have contributed so greatly to the fight against cancer.
Beyond their job responsibilities, Celgene employees also show their commitment to patients by participating in programs such as the Leukemia and Lymphoma Society’s Light The Night Walks and the Pancreatic Cancer Action Network’s Purple Strides campaign, raising funds for disease research.
To demonstrate its commitment to the environment, Celgene has continued to advance environmental management efforts to reduce carbon emission and increase water reuse and recycling programs. Nowhere is the company’s corporate sustainability leadership more evident than in its LEED-certified facilities in San Diego and San Francisco and its MINERGIE Standard certified international headquarters in Boudry, Switzerland.
Since 2009, Celgene Global Health (CGH) has been actively searching for treatments for neglected diseases—such as sleeping sickness, Chagas disease and malaria—that predominantly affect developing nations. Additionally, CGH is identifying key stakeholders and collaborating with partners globally to find innovative solutions for healthcare challenges in the developing world.
Most neglected disease research takes place in academic and nonprofits laboratories where access to resources, such as large chemical libraries to screen for potential therapies and platforms for preclinical and clinical research, is limited. That is where Celgene—with its commitment to improving the lives of patients through innovation—has been helping through public-private partnerships.
Celgene’s commitment to growing its neglected disease collaborations can already be seen. Last year, CGH bolstered its collaboration with the Drugs for Neglected Diseases initiative (DNDi). Together, Celgene and DNDi have been screening therapeutic candidates for neglected disease since 2011. Also in 2014, CGH teamed up with H3-D, South Africa’s first drug discovery and development center, to identify novel candidates for the treatment of tuberculosis, a disease that still kills more than a million people worldwide annually.
“Through its investment in medical innovation, passionate employees and strategic partnerships, Celgene is continuing to demonstrate its commitment to improving the lives of patients through medical innovation,” Khan said.